Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TSB-9-W1 (Taiwan Sunpan Biotechnology Development Co., Ltd.)
- Development stage
- Unknown
- Lead developer
- Taiwan Sunpan Biotechnology Development
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
TSB-9-W1 is an investigational, orally administered **botanical extract** derived from gamboge resin obtained from *Garcinia* species. It is a milled 5-micrometer form of TSB-9, a preparation comprising 90% gamboge resin extract and 10% brown sugar. The heterogeneous extract contains multiple constituents, including gambogic acid, formoxanthone A, betulin, betulinic acid, morellic acid, isomorellic acid, isogambogic acid, isomorellinol, and desoxymorellin. It has been evaluated by Taiwan Sunpan Biotechnology Development in a completed Phase 1 dose-escalation study in previously treated metastatic colorectal cancer. Its proposed anticancer activity is multifactorial and includes induction of tumor-cell apoptosis, cytotoxicity, and inhibition of tumor-cell proliferation; no single validated molecular target has been established for the complete extract.
- Brand names
- IDS
- Other names
- gamboge resin extract TSB-9-W1
Beyond the preview
Go deeper on TSB-9-W1 (Taiwan Sunpan Biotechnology Development Co., Ltd.).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TSB-9-W1 (Taiwan Sunpan Biotechnology Development Co., Ltd.).